Poly(DMAEMA-NVP)-b-PEG-galactose as gene delivery vector for hepatocytes

Area of Science:

• Biomaterials Science
• Gene Therapy
• Polymer Chemistry

Background:

• Developing effective non-viral gene delivery vectors is crucial for gene therapy.
• Cationic polymers and poly(ethylene glycol) (PEG) offer potential for DNA complexation and biocompatibility.
• Targeting specific cell receptors, like the asialoglycoprotein receptor on hepatocytes, can improve delivery efficiency.

Purpose of the Study:

• To synthesize and characterize a novel block copolymer, poly(2-(dimethylamino)ethyl methacrylate (DMAEMA)-co-N-vinyl-2-pyrrolidone (NVP))-b-PEG-galactose, for gene delivery.
• To evaluate the in vitro gene transfection efficiency of the developed system in HepG2 cells.
• To assess the impact of an endosomolytic peptide (KALA) and serum proteins on transfection efficacy.

Main Methods:

• Synthesis of poly(DMAEMA-NVP) with a terminal carboxylic group via free radical polymerization.
• Conjugation of the polymer with PEG-bis(amine) and incorporation of a galactose moiety for hepatocyte targeting.
• Formation of poly(DMAEMA-NVP)-b-PEG-galactose/DNA complexes and subsequent coating with KALA peptide.
• In vitro transfection assays using RSV luciferase plasmid in HepG2 cells.

Main Results:

• Poly(DMAEMA-NVP)-b-PEG-galactose/DNA complexes formed nanoparticles (approx. 200 nm) with slightly negative surface charge.
• Complexes coated with KALA peptide showed enhanced gene transfection, particularly at higher KALA/DNA ratios.
• The presence of serum proteins significantly boosted transfection efficiency, comparable to Lipofectamine plus, due to PEG and galactose moieties.

Conclusions:

• The engineered poly(DMAEMA-NVP)-b-PEG-galactose block copolymer, when formulated with KALA peptide, demonstrates high gene transfection efficiency.
• The galactose moiety facilitates specific targeting, while the PEG block and KALA peptide enhance cellular uptake and endosomal escape.
• This system shows promise as an effective non-viral gene delivery vector, achieving efficiency comparable to commercial standards.